| Literature DB >> 33337694 |
Kai Pihlainen1, Heikki Kyröläinen2,3, Matti Santtila3, Tommi Ojanen4, Jani Raitanen5,6, Keijo Häkkinen2.
Abstract
ABSTRACT: Pihlainen, K, Kyröläinen, H, Santtila, M, Ojanen, T, Raitanen, J, and Häkkinen, K. Effects of combined strength and endurance training on body composition, physical fitness, and serum hormones during a 6-month crisis management operation. J Strength Cond Res 36(9): 2361-2370, 2022-Very few studies have examined the impact of training interventions on soldier readiness during an international military operation. Therefore, the present study investigated the effects of combined strength and endurance training on body composition, physical performance, and hormonal status during a 6-month international military deployment consisting of typical peacekeeping tasks, e.g., patrolling, observation, and on-base duties. Soldiers ( n = 78) were randomly allocated to a control group (C) or one of 3 combined whole-body strength and endurance training groups with varying strength-to-endurance training emphasis (Es = 25/75%, SE = 50/50% or Se = 75/25% of strength/endurance training). Body composition, physical performance (3000-m run, standing long jump [SLJ], isometric maximal voluntary contraction of the lower [MVC lower] and upper extremities [MVC upper ], muscle endurance tests), and selected serum hormone concentrations were determined prior to training (PRE), and after 9 (MID) and 19 (POST) weeks of training. Within- and between-group changes were analyzed using linear regression models. The average combined strength and endurance training frequency of the total subject group was 3 ± 2 training sessions per week. No changes were observed in physical performance variables in the intervention groups, whereas SLJ decreased by 1.9% in C ( p < 0.05). Maximal voluntary contraction lower increased by 12.8% in the combined intervention group ( p < 0.05), and this was significantly different to C ( p < 0.05). Testosterone-to-cortisol ratio increased in SE and Se ( p < 0.05), whereas no change was observed in C. The intervention groups maintained or improved their physical performance during deployment, which is beneficial for operational readiness. However, the high interindividual variation observed in training adaptations highlights the importance of training individualization during prolonged military operations.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33337694 PMCID: PMC9394488 DOI: 10.1519/JSC.0000000000003902
Source DB: PubMed Journal: J Strength Cond Res ISSN: 1064-8011 Impact factor: 4.415
Physical performance variables (mean and SD) of the combined strength and endurance training groups and the control group at baseline (PRE), after 9 (MID) and 19 weeks (POST) and their changes within groups, based on unstandardized coefficients (Coef.) and 95% confidence intervals (CI) from linear regression models.*†
| n | PRE | MID | POST | Within groups | |||
| PRE-MID | PRE-POST | MID-POST | |||||
| Coef. (95% CI) | Coef. (95% CI) | Coef. (95% CI) | |||||
| 3000-m running test (min:s) | |||||||
| | 18 | 14:11 ± 1:36 | 13:50 ± 1:17 | 14:00 ± 1:29 | −0:16 (−0:36 to 0:04) | −0:08 (−0:27 to 0:11) | 0:10 (−0:07 to 0:27) |
| Se | 10 | 13:49 ± 1:18 | 13:53 ± 0:52 | 13:52 ± 0:57 | 0:04 (−0:23 to 0:31) | 0:03 (−0:22 to 0:28) | −0:01 (−0:23 to 0:21) |
| Es | 10 | 13:25 ± 1:34 | 13:18 ± 1:33 | 13:23 ± 1:32 | −0:12 (−0:39 to 0:16) | −0:05 (−0:30 to 0:21) | 0:04 (−0:19 to 0:27) |
| C | 17 | 13:43 ± 1:12 | 13:49 ± 1:24 | 13:52 ± 1:28 | 0:05 (−0:16 to 0:26) | 0:09 (−0:11 to 0:28) | 0:03 (−0:14 to 0:20) |
| | 38 | 13:53 ± 1:31 | 13:42 ± 1:15 | 13:48 ± 1:22 | −0:10 (−0:23 to 0:04) | −0:04 (−0:17 to 0:08) | 0:06 (−0:06 to 0:17) |
| Military simulation test (min:s) | |||||||
| | 15 | 2:33 ± 0:27 | 2:21 ± 0:18 | 2:10 ± 0:16 | |||
| Se | 9 | 2:29 ± 0:24 | 2:15 ± 0:18 | 2:07 ± 0:20 | |||
| Es | 11 | 2:22 ± 0:22 | 2:12 ± 0:16 | 2:06 ± 0:15 | |||
| C | 12 | 2:27 ± 0:19 | 2:19 ± 0:14 | 2:08 ± 0:17 | |||
| | 35 | 2:29 ± 0:25 | 2:17 ± 0:17 | 2:08 ± 0:16 | |||
| Standing long jump (cm) | |||||||
| | 18 | 234 ± 26 | 237 ± 27 | 231 ± 28 | 2.8 (−0.9 to 6.6) | −3.2 (−7.8 to 1.4) | |
| Se | 12 | 238 ± 21 | 238 ± 20 | 236 ± 17 | −0.1 (−4.7 to 4.5) | 2.1 (−7.8 to 3.5) | −2.0 (−6.9 to 2.8) |
| Es | 15 | 238 ± 20 | 241 ± 22 | 238 ± 22 | 3.1 (−1.0 to 7.3) | 0.9 (−4.1 to 6.0) | −2.0 (−6.4 to 2.3) |
| C | 19 | 236 ± 25 | 235 ± 28 | 230 ± 29 | −1.3 (−4.9 to 2.4) | ||
| | 45 | 236 ± 22 | 238 ± 23 | 235 ± 25 | 2.2 (−0.2 to 4.5) | −1.5 (−4.4 to 1.4) | |
| Maximal voluntary force of the lower extremities ( | |||||||
| | 19 | 4,216 ± 797 | 4,547 ± 964 | 4,651 ± 1,036 | 97 (−130 to 324) | ||
| Se | 12 | 4,168 ± 1,110 | 4,997 ± 1,598 | 4,908 ± 1,448 | −34 (−323 to 255) | ||
| Es | 15 | 4,337 ± 735 | 4,609 ± 828 | 4,863 ± 982 | 264 (−17 to 544) | 256 (−0.1 to 511) | |
| C | 19 | 4,196 ± 1,081 | 4,395 ± 1,191 | 4,325 ± 1,013 | 201 (−47 to 450) | 129 (−138 to 397) | −98 (−326 to 131) |
| | 46 | 4,243 ± 853 | 4,684 ± 1,116 | 4,787 ± 1,121 | 115 (−31 to 262) | ||
| Maximal voluntary force of the upper extremities ( | |||||||
| | 20 | 1,150 ± 261 | 1,177 ± 263 | 1,167 ± 263 | 27 (−9 to 64) | 18 (−23 to 60) | −9 (−42 to 25) |
| Se | 11 | 1,121 ± 204 | 1,142 ± 213 | 1,163 ± 210 | 20 (−29 to 69) | 40 (−16 to 95) | 18 (−27 to 64) |
| Es | 15 | 1,199 ± 185 | 1,228 ± 172 | 1,204 ± 172 | 33(-9 to 74) | 12 (−36 to 59) | −19 (−58 to 20) |
| C | 19 | 1,104 ± 253 | 1,137 ± 250 | 1,102 ± 232 | 30 (−7 to 68) | −6 (−48 to 36) | |
| | 46 | 1,159 ± 223 | 1,185 ± 223 | 1,178 ± 220 | 21 (−6 to 48) | −6 (−28 to 16) | |
| Push-ups (repetitions in 1 minute) | |||||||
| | 20 | 40 ± 12 | 41 ± 10 | 44 ± 13 | 0.7 (−2.0 to 3.5) |
|
|
| Se | 11 | 37 ± 11 | 41 ± 11 | 46 ± 11 | 2.7 (−1.0 to 6.4) |
|
|
| Es | 15 | 44 ± 14 | 46 ± 15 | 50 ± 13 | 2.1 (−1.1 to 5.3) |
|
|
| C | 19 | 39 ± 13 | 39 ± 12 | 45 ± 16 | −0.2 (−3.0 to 2.6) |
|
|
| | 46 | 41 ± 13 | 42 ± 12 | 47 ± 13 | 1.6 (−0.2 to 3.4) |
|
|
| Sit-ups (repetitions in 1 minute) | |||||||
| | 20 | 45 ± 10 | 47 ± 9 | 48 ± 8 |
|
| 0.9 (−0.6 to 2.4) |
| Se | 12 | 46 ± 7 | 47 ± 8 | 49 ± 9 | 0.6 (−1.4 to 2.7) |
|
|
| Es | 15 | 48 ± 9 | 50 ± 8 | 50 ± 9 |
|
| −0.0 (−1.8 to 1.8) |
| C | 19 | 46 ± 10 | 46 ± 10 | 48 ± 10 | −0.1 (−1.7 to 1.5) | 1.8 (−0.3 to 3.8) |
|
| | 47 | 46 ± 9 | 48 ± 8 | 49 ± 9 |
|
| 0.9 (−0.1 to 1.9) |
| Pull-ups (repetition maximum) | |||||||
| | 20 | 9 ± 6 | 11 ± 5 | 12 ± 6 |
|
| 0.9 (−0.0 to 1.9) |
| Se | 12 | 9 ± 4 | 10 ± 6 | 12 ± 6 | 0.8 (−0.5 to 2.2) |
|
|
| Es | 15 | 12 ± 5 | 13 ± 6 | 15 ± 6 |
|
|
|
| C | 19 | 9 ± 5 | 11 ± 6 | 12 ± 6 |
|
| 0.9 (−0.1 to 2.0) |
| | 47 | 10 ± 5 | 11 ± 6 | 13 ± 6 |
|
|
|
MID = first (9 weeks) follow-up measurement; POST = second (19 weeks) follow-up measurement; SE = 50% strength training group; Se = 75% strength training group; Es = 25% strength training group; C = control group.
Bolded values, p < 0.05.
Unstandardized regression coefficients (coef.) with p-values <0.05 for the PRE-POST relative change in 3,000 m running test performance (3000-m), maximal isometric force of the lower extremity extensor muscles (MVClower), muscle mass (SMM), and fat mass (FATM).*†
| ∆ % 3000-m | ∆ % MVClower | ∆ % SMM | ∆ % FATM | |||||||||
| n | Coef. |
| n | Coef. |
| n | Coef. |
| n | Coef. |
| |
| Strength training frequency (times·wk−1) | 43 | 2.16 | <0.001 | 60 | 0.98 | 0.009 | ||||||
| LB strength training load (×1,000 kg) | 54 | 0.99 | 0.002 | |||||||||
| ∆ PRE-POST body mass index (%) | 54 | 0.75 | <0.001 | |||||||||
| PRE FATM (kg) | 55 | −0.41 | 0.034 | |||||||||
| ∆ PRE-POST FATM (%) | 54 | 0.11 | <0.001 | |||||||||
| ∆ PRE-POST SLJ (%) | 64 | 1.10 | 0.012 | |||||||||
| ∆ PRE-POST MST (%) | 49 | 0.35 | <0.001 | 58 | −0.61 | 0.028 | 62 | −0.11 | 0.027 | 62 | 0.83 | 0.009 |
| ∆ PRE-POST sit-up (%) | 53 | −0.10 | 0.042 | 72 | −0.43 | 0.024 | ||||||
| ∆ PRE-POST pull-up (%) | 53 | −0.03 | 0.020 | |||||||||
| PRE MVClower (N) | 55 | 0.0013 | 0.046 | |||||||||
| ∆ PRE-POST MVClower (%) | 53 | −0.09 | 0.045 | |||||||||
| ∆ PRE-POST MVCupper (%) | 71 | 0.091 | 0.024 | |||||||||
| ∆ PRE-POST 3000-m (%) | 64 | 1.87 | 0.001 | |||||||||
| ∆ PRE-POST SHBG (%) | 50 | −0.029 | 0.021 | |||||||||
| ∆ PRE-POST TES:SHBG (%) | 50 | 0.019 | 0.041 | |||||||||
| PRE IGF1 (nmol·L−1) | 50 | −0.69 | 0.012 | |||||||||
| ∆ PRE-POST IGF1 (%) | 50 | −2.15 | 0.003 | |||||||||
PRE = baseline measurement at the beginning of the operation; POST = final measurement at the end of the operation; LB = lower body; FATM = fat mass; kg = kilogram; SLJ = standing long jump; MST = military simulation test; MVCupper = maximal isometric force of the upper extremity extensor muscles; SHBG = Sex-hormone binding globulin, TES:SHBG = Testosterone to sex-hormone binding globulin ratio; IGF1 = Insulin-like growth factor-1.
Explanatory variables are adjusted for the baseline value of the outcome.
Group-wise weekly mean ± SD and range of the training frequency, volume of endurance training and volume load of strength training in the combined strength and endurance training groups and the control group during the operation.*
| Training variables |
| Se | Es | C | ||||
| Mean ± | Range | Mean ± | Range | Mean ± | Range | Mean ± | Range | |
| Endurance training frequency (times) | 1.5 ± 0.6 | 0.6–3.1 | 0.7 ± 0.6 | 0.0–2.0 | 2.2 ± 0.8 | 0.8–3.5 | 2.2 ± 1.7 | 0.0–6.5 |
| Strength training frequency (times) | 1.6 ± 0.8 | 0.4–2.8 | 1.7 ± 0.5 | 1.1–2.4 | 0.8 ± 0.4 | 0.0–1.4 | 1.8 ± 1.4 | 0.0–4.7 |
| Total training frequency (times) | 3.1 ± 1.2 | 1.2–5.0 | 2.4 ± 0.7 | 1.4–3.7 | 3.0 ± 1.1 | 0.8–4.4 | 4.0 ± 2.0 | 1.6–8.6 |
| LIT (<75% HRpeak) volume (min) | 62 ± 30 | 30–151 | 50 ± 18 | 30–81 | 78 ± 32 | 36–144 | 55 ± 37 | 20–125 |
| MIT (75–85% HRpeak) volume (min) | 48 ± 13 | 24–67 | 49 ± 17 | 30–72 | 43 ± 12 | 27–60 | 43 ± 15 | 21–65 |
| HIT (>85% HRpeak) volume (min) | 38 ± 22 | 16–77 | 30 ± 11 | 22–38 | 33 ± 12 | 23–53 | 17 ± 5 | 13–20 |
| LB strength training volume load (×1,000 kg) | 15.7 ± 7.2 | 3.0–31.1 | 16.8 ± 6.5 | 4.4–26.8 | 16.2 ± 7.0 | 4.7–27.7 | 10.8 ± 7.6 | 3.4–34.9 |
| UB strength training volume load (×1,000 kg) | 11.2 ± 4.5 | 4.2–20.8 | 10.0 ± 3.0 | 6.2–15.0 | 10.1 ± 4.2 | 1.8–17.3 | 15.0 ± 9.3 | 3.8–34.5 |
SE = 50% strength training group; Se = 75% strength training group; Es = 25% strength training group; C = control group; LIT = low-intensity endurance training; MIT = moderate-intensity endurance training; HIT = high-intensity endurance training; LB = lower body; UB = upper body.
Figure 1.Within-group means and SDs for muscle mass, 3000-m running test, military simulation test and testosterone-to-cortisol ratio of the combined strength and endurance training groups and the control group during the operation. *p < 0.05; **p < 0.01; ***p < 0.001. Abbreviations: PRE, baseline; MID, first (9 weeks) follow-up measurement; POST, second (19 weeks) follow-up measurement; SE, 50% strength training group; Se, 75% strength training group; Es, 25% strength training group, C, control group.
Figure 2.Individual and group mean (bolded line) changes in skeletal muscle mass, fat mass, maximal voluntary force of the lower extremities, and 3000-m running performance of the combined strength and endurance training groups and the control group during the operation. *Significant within-group change compared to PRE (p < 0.05). Abbreviations: PRE, baseline; MID, first (9 weeks) follow-up measurement; POST, second (19 weeks) follow-up measurement; SE, 50% strength training group; Se, 75% strength training group; Es, 25% strength training group, C, control group; MVClower, maximal voluntary force of the lower extremities.
Serum anabolic and catabolic biomarkers (mean and SD) of the combined strength and endurance training groups and the control group at baseline (PRE), after 9 (MID) and 19 weeks (POST) and their changes within groups, based on unstandardized coefficients (Coef.) and 95% confidence intervals (CI) from linear regression models.*†
| n | PRE | MID | POST | Within groups | |||
| PRE-MID | PRE-POST | MID-POST | |||||
| Coef. (95% CI) | Coef. (95% CI) | Coef. (95% CI) | |||||
| Testosterone (nmol·L−1) | |||||||
| | 19 | 15.4 ± 3.9 | 16.4 ± 3.7 | 16.7 ± 2.9 | 0.7 (−0.8 to 2.3) | 0.9 (−0.5 to 2.3) | −0.3 (−1.8 to 1.2) |
| Se | 11 | 15.4 ± 2.5 | 15.9 ± 2.4 | 17.4 ± 2.7 | 0.2 (−1.8 to 2.2) | 1.7 (−0.2 to 3.6) | 0.7 (−1.3 to 2.7) |
| Es | 12 | 16.9 ± 7.1 | 18.0 ± 4.9 | 19.0 ± 5.1 | 1.5 (−0.4 to 3.5) |
| 1.5 (−0.4 to 3.4) |
| C | 16 | 16.3 ± 4.5 | 18.6 ± 4.6 | 17.2 ± 3.4 |
| 1.1 (−0.5 to 2.7) | −0.5 (−2.2 to 1.1) |
| | 42 | 15.9 ± 4.7 | 16.7 ± 3.8 | 17.6 ± 3.6 | 0.8 (−0.2 to 1.8) |
| 0.5 (−0.5 to 1.5) |
| Cortisol (nmol·L−1) | |||||||
| | 19 | 431 ± 74 | 421 ± 127 | 385 ± 130 | −7 (−61 to 47) | −44 (−98 to 9) | −55 (−113 to 2) |
| Se | 11 | 430 ± 97 | 459 ± 95 | 402 ± 156 | 31 (−40 to 102) | −27 (−98 to 43) | −48 (−123 to 27) |
| Es | 12 | 455 ± 114 | 453 ± 132 | 409 ± 118 | 20 (−49 to 88) | −33 (−101 to 35) | −39 (−111 to 33) |
| C | 16 | 401 ± 118 | 465 ± 109 | 412 ± 105 | 42 (−17 to 102) | −2 (−61 to 57) | −39 (−102 to 23) |
| | 42 | 438 ± 91 | 440 ± 120 | 396 ± 131 | 10 (−26 to 47) |
|
|
| Insulin-like growth factor-1 (nmol·L−1) | |||||||
| | 19 | 27.9 ± 9.3 | 25.2 ± 10.2 | 23.9 ± 8.6 | −2.6 (−5.7 to 0.5) | −3.9 (−7.9 to 0.05) | −2.3 (−6.1 to 1.5) |
| Se | 10 | 27.4 ± 10.4 | 27.6 ± 9.5 | 26.8 ± 13.9 | 0.0 (−4.3 to 4.3) | −0.7 (−6.2 to 4.7) | −0.7 (−5.9 to 4.6) |
| Es | 12 | 29.8 ± 10.1 | 30.7 ± 8.3 | 28.0 ± 10.2 | 1.6 (−2.3 to 5.6) | −0.7 (−5.7 to 4.3) | −1.3 (−6.2 to 3.5) |
| C | 16 | 26.0 ± 9.1 | 27.3 ± 8.5 | 27.5 ± 7.2 | 0.8 (−2.7 to 4.2) | 0.7 (−3.7 to 5.0) | 0.2 (−3.9 to 4.3) |
| | 41 | 28.3 ± 9.6 | 27.4 ± 9.5 | 25.8 ± 10.4 | −0.7 (−2.8 to 1.4) | −2.2 (−4.9 to 0.5) | −1.6 (−4.1 to 0.9) |
| Sex-hormone binding globulin (nmol·L−1) | |||||||
| | 19 | 31.0 ± 10.2 | 25.7 ± 8.3 | 23.6 ± 10.4 |
|
| −2.8 (−6.7 to 1.1) |
| Se | 11 | 32.4 ± 11.8 | 35.6 ± 8.6 | 22.5 ± 8.9 | 3.2 (−1.2 to 7.7) |
|
|
| Es | 12 | 34.7 ± 14.9 | 32.8 ± 11.9 | 30.9 ± 16.6 | −0.8 (−5.0 to 3.5) | −3.0 (−7.8 to 1.9) | −1.6 (−6.3 to 3.1) |
| C | 15 | 32.2 ± 11.9 | 32.4 ± 10.1 | 27.2 ± 9.8 | 0.1 (−3.7 to 3.9) |
|
|
| | 42 | 32.4 ± 11.9 | 30.3 ± 10.3 | 25.4 ± 12.4 | −2.1 (−4.5 to 0.4) |
|
|
| Testosterone-to-cortisol ratio | |||||||
| | 18 | 0.037 ± 0.010 | 0.041 ± 0.012 | 0.047 ± 0.017 | 0.001 (−0.003 to 0.006) |
| 0.008 (−0.001 to 0.016) |
| Se | 11 | 0.038 ± 0.013 | 0.036 ± 0.007 | 0.050 ± 0.021 | −0.004 (−0.010 to 0.002) |
|
|
| Es | 11 | 0.040 ± 0.015 | 0.039 ± 0.009 | 0.046 ± 0.014 | −0.001 (−0.007 to 0.005) | 0.006 (−0.003 to 0.014) | 0.007 (−0.004 to 0.018) |
| C | 15 | 0.045 ± 0.022 | 0.040 ± 0.010 | 0.045 ± 0.019 | −0.001 (−0.007 to 0.004) | 0.001 (−0.006 to 0.008) | 0.005 (−0.004 to 0.015) |
| | 40 | 0.038 ± 0.012 | 0.039 ± 0.010 | 0.048 ± 0.017 | −0.001 (−0.004 to 0.002) |
|
|
| Testosterone to sex-hormone binding globulin ratio | |||||||
| | 17 | 0.50 ± 0.17 | 0.63 ± 0.13 | 0.75 ± 0.26 |
|
|
|
| Se | 10 | 0.52 ± 0.20 | 0.45 ± 0.08 | 0.79 ± 0.25 | −0.07 (−0.16 to 0.02) |
|
|
| Es | 11 | 0.52 ± 0.13 | 0.55 ± 0.14 | 0.64 ± 0.18 | 0.03 (−0.06 to 0.12) |
| 0.09 (−0.04 to 0.23) |
| C | 16 | 0.55 ± 0.23 | 0.58 ± 0.21 | 0.68 ± 0.29 | 0.06 (−0.02 to 0.13) |
| 0.10 (−0.01 to 0.21) |
| | 38 | 0.51 ± 0.16 | 0.56 ± 0.16 | 0.73 ± 0.24 | 0.04 (−0.01 to 0.09) |
|
|
MID = first (9 weeks) follow-up measurement; POST = second (19 weeks) follow-up measurement; SE = 50% strength training group; Se = 75% strength training group; Es = 25% strength training group; C = control group.
Bolded values, p < 0.05.